^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Devyser BRCA NGS

    Company:
    Devyser
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    1year
    Novel pathogenic mutations in BRCA1 gene that may influence the interaction of BRCA1 protein with BARD1 protein in breast cancer patients (AACR 2023)
    In, conclusion, investigating the three selected pathogenic mutations showed a clear impact on the structure of the protein favored different types of bonds in the active site that may alter the interaction between BRCA1 and BARD1. This study has a beneficial role to investigate the impact of BRCA1 mutations on the structural stability of the protein and thereby the risk of BC development
    Clinical • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • BARD1 (BRCA1 Associated RING Domain 1)
    |
    BRCA1 mutation • BARD1 mutation
    |
    Devyser BRCA NGS
    2years
    Shuwen Biotech announce agreement with Devyser to commercialize breast cancer tests in China (Shuwen Biotech Press Release)
    "Shuwen Biotech...today announces that it has entered into a distribution agreement with Devyser Diagnostics...to market and support Devyser BRCA NGS and other oncology kits in China. Under the terms of the agreement, Shuwen will distribute the Devyser kits in China and also offer testing and NGS data analysis services with the Devyser kits in its CAP-accredited clinical labs in China."
    Licensing / partnership
    |
    Devyser BRCA NGS
    2years
    Association of some oncogenic viruses with BRCA gene mutations in breast cancer women (BGICC 2022)
    Results suggested possible risk factors associated with the presence of both oncogenic viruses and BRCA mutations, which might in turn affected management of BC disease, but larger sample size is still needed to evaluate such a correlation.
    Clinical • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • BRCA mutation
    |
    Devyser BRCA NGS